Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M <sup>pro</sup> and cathepsin L
M. Sacco(University of South Florida), Jun Wang(Rutgers Sexual and Reproductive Health and Rights), Brett L. Hurst(Utah State University), Ang Gao(Beijing University of Posts and Telecommunications), E. Bart Tarbet(Utah State University), Panagiotis Lagarias(National and Kapodistrian University of Athens), Yanmei Hu(University of Arizona), Xiangzhi Meng(University of California, Los Angeles), Chunlong Ma(University of Arizona), Yan Xiang(Sichuan University), Antonios Kolocouris(National and Kapodistrian University of Athens), Peter H. Dube(Boehringer Ingelheim (United States)), Michael T. Marty(University of Arizona), Yu Chen(University of South Florida), Xiujun Zhang(Tianjin University of Traditional Chinese Medicine), Naoya Kitamura(University of Arizona), Julia A. Townsend(University of Arizona)
Cited by 400
Related Papers
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
|Nature|2021|216
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
|ACS Central Science|2021|200
The <i>in vitro</i> antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
|Emerging Microbes & Infections|2021|190
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
|Journal of Medicinal Chemistry|2021|168
Role of Human β-Defensin-2 during Tumor Necrosis Factor-α/NF-κB-mediated Innate Antiviral Response against Human Respiratory Syncytial Virus
|Journal of Biological Chemistry|2008|159